Jefferies Initiates Coverage On Electra Therapeutics with Buy Rating, Announces Price Target of $32
Jefferies analyst Akash Tewari initiates coverage on Electra Therapeutics (NASDAQ:ETRA) with a Buy rating and announces Price Target of $32.
A big investment bank thinks Electra Therapeutics is worth buying and could reach $32. When experts start following a new company with confidence, it might mean they see something promising ahead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.